Cell reprogramming for the treatment of multiple sclerosis


15.185 out of 100.000 euros

15.185 euros raised
Thanks to all!


Precipita in figures


In the world, more than 2.5 million people suffer from Multiple Sclerosis. In Spain, more than 50,000 people suffer from it.

The project
Who is behind

What is our goal?

Multiple Sclerosis (MS) is a chronic inflammatory and autoimmune neurodegenerative disease characterised by the emergence of demyelinating lesions and of axonal damage in the central nervous system. It is the most frequent cause of non-traumatic neurological disability among young adults, mostly women.  70% of cases are diagnosed between 20 and 40 years old, therefore the impact of this disease in the personal, work and family life of these patients is very high.

Its natural evolution entails serious neurological deficits: loss of the movement, coordination, sensitivity, balance, vision, bowel control... which implies a gradual increase in the disability level and a progressive deterioration of the life quality. Although its cause is unknown, all the clues indicate that it occurs in people who are genetically predisposed on whom any environmental factor, that has not been identified yet, acts.

The main goal of this project is to obtain a treatment for the regeneration of the central nervous system in patients with Multiple Sclerosis. We will try to identify the factors related to age that act as genetic regulators in the repair of the myelin sheaths and in the neurodegeneration in the central nervous system. In this way, those who suffer from Multiple Sclerosis can have their damaged nervous cells repaired, prevent damages to the healthy cells and, therefore, improve their quality of life and maybe recover the lost functions.

To reach this goal we will develop a simple and reproducible experimental neuronal model with the different phases of the development of the disease, starting from induced pluripotent stem cells (iPSCs) (adult cells genetically reprogrammed to reach similar state to stem cells). We will obtain iPSCs from somatic cells of patients of different ages with Multiple Sclerosis, which will allow us to understand the disease evolution with aging and to test the effectiveness of experimental drugs and other advanced therapies avoiding the use of animals in the early stage of the experimentation.

Abaout Precipita
About us
Contact us
C/Pintor Murillo, 15
28100 Alcobendas (Madrid) - España
T.+(00 34) 91 425 09 09
A project from :Logo Ministerio
FECYT 2020. All right reserved
Legal terms | Privacy policy | Cookies policy
Powered by StockCrowd  Powered by StockCrowd
Información que debes conocer
Este sitio web utiliza cookies, para conocer nuestra política de cookies haga click aquí. Si estás de acuerdo con nuestra política de cookies haga click en el botón continuar.